JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A8236 Regorafenib
4 Citation

Target: Raf|VEGFR|PDGFR|c-Kit|RET

Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1

≥25.04 mg/mL
A2942 Masitinib (AB1010)

Target: PDGFR|c-Kit|Lyn

Summary: Tyrosine kinase inhibitor, potent and selective

≥24.95 mg/mL
A1805 Imatinib Mesylate (STI571)

Target: PDGFR|c-Kit|Bcr-Abl

Summary: Abl/c-kit/PDGFR inhibitor

≥29.5 mg/mL
A2168 Dovitinib (TKI-258, CHIR-258)
2 Citation

Target: FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Multitargeted RTK inhibitor

insoluble in H2O; insoluble in EtOH; ≥36.35 mg/mL
A8370 Axitinib (AG 013736)
1 Citation

Target: VEGFR|PDGFR|c-Kit

Summary: VEGFR1/ c-Kit inhibitor

insoluble in H2O; ≥19.3 mg/mL
A8550 Telatinib (BAY 57-9352)

Target: VEGFR|PDGFR|c-Kit

Summary: VEGFR-2/-3,PDGFR-β and c-Kit inhibitor

insoluble in H2O; insoluble in EtOH; ≥20.5 mg/mL
B5835 AZD2932

Target: FLT3|VEGFR|PDGFR|c-Kit

Summary: inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit

Soluble in DMSO
B5854 Pexidartinib (PLX3397)
3 Citation

Target: FLT3|c-Kit|CSF1R

Summary: CSF-1R inhibitor

insoluble in EtOH; insoluble in H2O; ≥20.9 mg/mL
B5953 Dovitinib (TKI258) Lactate

Target: CSF-1R|FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Oral tyrosine kinase inhibitor (TKI) against FGFR1–3, VEGFR1–3, and platelet-derived growth factor receptor (PDGFR).

insoluble in EtOH; ≥10.62 mg/mL
B2171 Imatinib (STI571)

Target: PDGFR|c-Kit|Bcr-Abl

Summary: Protein-tyrosine kinase inhibitor

≥24.68 mg/mL